Anti-cancer strategies -
Body Type Quiz Find a Doctor - EverydayHealth Care Hydration Calculator Menopause Age Calculator Symptom Checker Weight Loss Calculator.
See All. DailyOM Courses. About DailyOM Most Popular Courses New Releases Trending Courses See All. By Eric Metcalf, MPH. Medically Reviewed. Walter Tsang, MD. Consider these anti-cancer diet guidelines: Eat plenty of fruits and vegetables.
Fruits and vegetables are full of vitamins and nutrients that are thought to reduce the risk of some types of cancer. Eating more plant-based foods also gives you little room for foods high in sugar.
Instead of filling up on processed or sugary foods, eat fruits and vegetables for snacks. The Mediterranean diet offers foods that fight cancer, focusing mostly on plant-based foods, such as fruits and vegetables, whole grains, legumes, and nuts. People who follow the Mediterranean diet choose cancer-fighting foods like olive oil over butter and fish instead of red meat.
Sip green tea throughout your day. Green tea is a powerful antioxidant and may be an important part of an anti-cancer diet. Green tea, a cancer-fighting food, may be helpful in preventing liver, breast, pancreatic, lung, esophageal, and skin cancer. Researchers report that a nontoxic chemical found in green tea, epigallocatechin-3 gallate, acts against urokinase an enzyme crucial for cancer growth.
One cup of green tea contains between and milligrams mg of this anti-tumor ingredient. Eat more tomatoes. Research confirms that the antioxidant lycopene, which is in tomatoes, may be more powerful than beta-carotene, alpha-carotene, and vitamin E.
Lycopene is a cancer-fighting food associated with protection against certain cancers such as prostate and lung cancer. Be sure to cook the tomatoes, as this method releases the lycopene and makes it available to your body.
Use olive oil. In Mediterranean countries, this monounsaturated fat is widely used for both cooking and salad oil and may be a cancer-fighting food. Breast cancer rates are 50 percent lower in Mediterranean countries than in the United States.
Snack on grapes. Red grapes have seeds filled with the superantioxidant activin. This cancer-fighting chemical, also found in red wine and red-grape juice, may offer significant protection against certain types of cancer, heart disease, and other chronic degenerative diseases.
Use garlic and onions abundantly. Research has found that garlic and onions can block the formation of nitrosamines, powerful carcinogens that target several sites in the body, usually the colon, liver, and breasts.
Indeed, the more pungent the garlic or onion, the more abundant the chemically active sulfur compounds that prevent cancer. Eat fish. Fatty fish — such as salmon, tuna, and herring — contain omega-3 fatty acids, a type of fatty acid that has been linked to a reduced risk of prostate cancer.
Another way to add omega-3s to your diet is by eating flaxseed. Be proactive, and make more room in your diet for the following foods that prevent cancer. Add Garlic to Your Anti-Cancer Diet. Berries Are Foods That Fight Cancer.
Tomatoes May Protect Men From Prostate Cancer. Add Cruciferous Vegetables to Your Anti-Cancer Diet. Drink Green Tea to Prevent Cancer. Whole Grains Are in the Front Lines Among Foods Fight Cancer. Turmeric May Reduce Cancer Risk. Add Leafy Green Vegetables to Your Anti-Cancer Diet.
Grapes Prevent Cancer From Beginning or Spreading. Cancer-Fighting Beans May Reduce Your Cancer Risk. Editorial Sources and Fact-Checking. Resources American Cancer Society Guideline for Diet and Physical Activity.
American Cancer Society. June 9, National Heart, Lung, and Blood Institute. March 8, American Institute for Cancer Research. November 3, Your Guide to Healthy Whole Grains. March 1, This is becoming more possible, as scientists estimate that we could prevent more than half of all cancers by better applying knowledge we already have.
That means taking what we know about the risk factors for, causes of, and development of many cancers and using that information to better monitor and identify anything abnormal before it becomes cancer and to encourage behaviors that help minimize the risk of getting cancer.
But changing human behavior is not easy. Getting more people to adopt and follow these preventive behaviors, especially among groups that have been medically underserved, could significantly lower the number of people being diagnosed with cancer. Researchers also continue to study how to reduce cancer disparities, limit exposure to risk factors, and intercept cancer identify and treat certain lesions before they become cancer , among other prevention approaches.
Thank you Anti-cancer strategies visiting Natural Liver Support Remedies. You are using Anto-cancer browser version with limited support for CSS. To Shrategies the best experience, we recommend you use a more syrategies to Anti-cancer strategies browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Tumor cells rely mainly on glycolysis for energy production even in the presence of sufficient oxygen, a phenomenon termed the Warburg effect, which is the most outstanding characteristic of energy metabolism in cancer cells. Protect yourself from cancer by adding Anti-cancer strategies anti-cancer foods Anti-cancer strategies etrategies diet. An strateiges diet is Anti-cancer strategies important strategy strategirs Anti-cancer strategies use to reduce your Anti-cancer strategies of cancer. The Green tea for anxiety Cancer Atrategies advises following the U. Dietary Guidelines, which is to consume at least 2½ to 3 cups of vegetables and 1½ to 2 cups of fruit each day roughly five servings total to reduce risk of cancer. An observational study that followedpeople over 30 years supports the recommendation, finding that doing so reduces the risk of dying from cancer, as well as cardiovascular and respiratory disease. In addition, researchers are finding that certain foods that prevent cancer may be an important part of an anti-cancer diet.Anti-cancer strategies -
Other ITIM-containing receptors are being extensively studied [ ]. For example, LIR-1 binding to HLA-G and other low affinity HLA ligands is expressed on approximately one-third of NK cells. An antibody blocking LIR-1 significantly potentiated the tumoricidal activity of NK cells in vitro and in vivo [ ].
In addition to KIRs, other MHC-recognizing receptors are also important in regulating NK cell functions and tumor eradication. Since most of the TAMs are M2 macrophages, several approaches have been explored to inhibit or deplete TAMs for cancer immunotherapy.
Several preclinical studies showed that tumor growth inhibition could be achieved through targeting these cytokines or with depletion of TAMs.
However, they have yet to be translated into clinical applications as these cytokines have other functions in addition to recruiting macrophages [ ].
SIRPα is a transmembrane protein expressed on macrophages, granulocytes, monocytes, dendritic cells and neurons. Virotherapy uses viruses to target and kill cancer cells, induce innate and adaptive immune response for cancer treatment. Adenoviruses, herpes viruses, measles viruses, coxsackie viruses, polioviruses, reoviruses, poxviruses and Newcastle disease viruses, among others, are some of the oncolytic viruses OVs under preclinical and clinical development for cancer therapy [ ].
Initially wild type viruses were used. So far, three OVs have been approved and used at clinic: Rigvir an oncolytic picornavirus [ ], H or Oncorine an adenovirus [ ] and talimogene laherparepvec, also known as T-vec a herpes simplex-1 virus encoding for GM-CSF [ ].
Several mechanisms have been proposed for the action of OVs. First, OVs can directly target, lyse and kill cancer cells. Cancer tropism can occur naturally with OVs as oncogenic signaling pathways are more active in cancer cells which can facilitate viral replication.
More recently, genetic engineering has been used to make cancer-specific OVs. Second, OVs can activate the innate immune response. Viral replication and destruction of tumor cells and release of viral DNA can induce innate immune response locally to kill more cancer cells. Third, OVs can induce adaptive immune response.
Fourth, OVs can be engineered to express transgenes to stimulate immune response. For example, talimogene laherparepvec expresses GM-CSF and was FDA approved for treatment of recurrent melanoma. Even though oncolytic virotherapy showed promising preclinical activities, clinical activities are still moderate.
In cutaneous melanoma, intratumoral injection of talimogene laherparepvec is associated with an overall response rate of One advantage of OVs is that they can be armed with transgenes and combined with several therapeutic interventions.
So far transgenes targeting every step along the anti-cancer immunity cycle have been studied at least in preclinical models Table 7 [ ]. For example, oncolytic adenovirus armed with bi-specific T cell engager BiTE has been demonstrated to induce both oncolysis by OV and engagement and activation of cytotoxic T cells which led to immune-mediated destruction of cancer cells both in vivo with tumor implants and in primary ex vivo patient specimens [ , ].
While most OVs armed with the transgenes listed on Table 8 are still at the preclinical stages, several clinical trials combining OVs with another therapeutic agent have been initiated [ ]. The most common combination therapy is OVs and ICBs.
These two agents have complementary mechanisms of anti-cancer immunity in that ICBs release the suppression of anti-cancer immune response while OVs stimulate the immune response. The combination was first tested in preclinical models with an oncolytic Newcastle disease virus NDV in combination with systemic CTLA-4 blockade [ ].
Local virotherapy induced abscopal effects and immune cell infiltration at distant tumors. In addition to talimogene laherparepvec, several other major OVs are being combined with ICBs in clinical trials.
OVs have also been tested in clinical trials with chemotherapy. This adenovirus expressed double-suicide genes: yeast cytosine deaminase yCD and herpes simplex virus 1 thymidine kinase HSV-1 TK [ ].
This combination was well tolerated in early clinical trials. Cancer vaccine is a targeted cancer immunotherapy that uses putative cancer antigen s or antigenic epitope s presented in protein, RNA, DNA, viral or bacterial vectors, cells or other means to stimulate anti-cancer immunity.
More recently, with the understanding of anti-cancer immunity and development of vaccine technology, deep sequencing and bioinformatics, personalized cancer vaccines showed promising clinical activities.
However, many patients do not respond. The reason for low efficacy for cancer vaccines is likely to be multifactorial. Cancer vaccines are used in patients whose immune system has already tolerated cancer and cancers can develop or have already developed an immunosuppressive TME that prevents anti-cancer immunity.
In contrast, vaccines for infectious diseases are exogenous antigens that hosts have not developed resistance. There are two major types of cancer vaccines: shared tumor-associated antigens TAA and unique tumor antigens Table 9. Cell differentiation antigens are a group of antigens expressed in differentiated tissues from which some cancers develop and share those antigens, such as glycoprotein gp , prostatic acid phosphate, and prostate-specific antigen PSA.
Overexpressed cell antigens are expressed in normal cells, but significantly upregulated in some cancer cells, such as mucin 1 MUC1 or epithelial membrane antigen, mesothelin and HER2. There are two major issues associated with shared TAAs.
First, the immune system has already developed tolerance to these antigens. Hence, even with strong adjuvants, co-stimulators or repeated vaccinations, anti-cancer immunity may develop, but is not sufficient to eliminate cancers. Second, these antigens are also expressed in some normal cells.
Unique tumor antigens include oncogenic viral antigens associated with viral infection and tumor neoantigens associated with cancer genomic alterations, such as mutations, frame shift and gene fusion.
The three most commonly studied viruses associated with cancers and cancer vaccines are hepatitis B virus, human papillomavirus HPV and Epstein—Barr virus EBV. Because these unique tumor antigens appear after the immune system has already developed, the central tolerance to these antigens and cross-reactivity to normal tissues are usually low and the likelihood of induction of immune response to them is high.
Several approaches have been used in clinic to deliver cancer antigens in order to elicit anti-cancer immunity Table 9. Cell-based vaccines use autologous cancer cells, antigen-presenting cells or allogeneic cells to deliver cancer vaccine antigens. When cancer cells are used, cells are treated in vitro, usually with radiation, to prevent further cell division before administration.
The advantage of cell-based vaccine is that specific target antigens do not need to be prospectively identified, and dendritic cells can present tumor antigens in the context of the MHC that can be further potentiated with a stimulatory cytokine.
Sipuleucel-T is FDA approved for treatment of metastatic prostate cancer and is comprised of autologous dendritic cells activated ex vivo with expression of a chimeric protein of immune stimulatory cytokine, GM-CSF, fused to a cell differentiation tumor antigen PAP.
In a Phase III clinical trial, the median overall survival OS of the sipuleucel-T group was about 4 months longer than the control cohort treated with placebo [ ]. However, the vaccine treatment was not associated with any biomarker PSA or radiological response.
Several other cell-based vaccines are also at clinical trials. Both gemogenovatucel-T and GVAX are tumor cell vaccines expressing GM-CSF to promote antigen presentation, activation and survival of dendritic cells.
Some other cellular vaccines are manipulated to down-regulate the expression of immunosuppressive factors. For example, belagenpumatucel-L is a mixture of four irradiated human NSCLC cell lines, transfected with a TGF-β2 antisense gene.
A higher response rate was observed in patients with NSCLC treated with higher doses of Belagenpumatucel-L [ ]. Gemogenovatucel-T expresses a bi-functional short hairpin RNA to knock down the expression of the enzyme furin which converts immunosuppressive TGF-β1 and TGF-β2 into active isoforms.
Even though those cell-based vaccines showed promising activities in preclinical models and stimulated immune response in patients, their clinical efficacy has yet to be proven [ ].
In addition to human cells, microorganisms such as bacteria and yeasts are also being explored for cancer vaccine therapy. Heated-inactivated bacteria and Bacillus Calmette-Guérin have been used in clinic to treat cancers for decades.
But strictly, they are not cancer vaccines as they do not carry tumor antigens. Other bacteria, such as Listeria, can deliver DNA- and RNA-encoded tumor antigens directly into mammalian cells, including APCs, and are being tested as cancer vaccine vehicles [ ]. For microorganisms, viral vectors have been studied as a vehicle to deliver cancer vaccines.
For viral vectors, in addition to its ability to induce innate and adaptive immune response, exogenous genes can be incorporated and expressed, including cytokines and tumor antigens.
One potential disadvantage of using a viral vector to deliver a cancer vaccine is that the immune response induced by previous vaccinations or infections of the same virus produces a neutralizing antibody and clears subsequent vaccinations. One approach is to administer the vaccine through intratumoral injection as talimogene laherparepvec.
Peptide vaccines have also been used in vaccine studies as T cells recognize tumor antigens presented by MHC. When short peptides are used, they can directly bind to MHC molecules on any nucleated cells.
As T cell activation requires the engagement of T cell receptors by antigens presented with MHC as well as a second signal from a co-stimulatory molecule, presentation of short peptide vaccines by nucleated cells other than APCs often induces T cell anergy and immune tolerance since other nucleated cells lack co-stimulatory signals.
To overcome the immune tolerance associated with short peptides, synthetic long peptides SLPs have been used. SLPs are preferentially taken up and processed by dendritic cells which also provide co-stimulatory molecules to prime and activate T cell immunity.
To further improve the efficacy, SLPs are often formulated with inflammatory adjuvants. For example, synthetic cancer neoantigen long peptide vaccines formulated with a toll-like receptor 3 TLR3 ligand poly-ICLC polyinosinic and polycytidylic acid induced strong anti-cancer immunity and clinical response [ ].
Systemic immune response was abolished in those patients who received the immunosuppressive steroid dexamethasone during vaccine priming. Peptides and proteins have also been formulated in nanoparticles to enhance its efficacy.
Furthermore, by optimizing the structure, surface charge and cell penetrating peptides, the efficacy of nanoparticles can possibly be further enhanced [ , ]. So far, various nanomaterials, such as polymeric materials, liposomes, micelles, silica nanoparticles, gold nanoparticles AuNPs and virus nanoparticles, have been studied in preclinical models with a few translated into clinical trials, but the efficacy is still yet to be validated [ ].
Instead of using peptides and proteins, DNA and RNA vaccines have also been translated into clinical trials [ ]. In addition to serving as vaccines, exogenous DNA and RNA can serve as immune stimulators, trigger nucleic acid sensors and activate dendritic cells through certain TLR and STING pathways.
One major disadvantage of naked DNA and RNA vaccine is their low delivery efficiency. To overcome this obstacle, various delivery methods have been developed, such as viral vectors and nanoparticles as discussed above, gene gun, electroporation and so on [ ].
Two coronavirus COVID mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [ , ]. Once immune cells are activated, they still need to go through the remaining four steps along the cycle: mobilize in the periphery, infiltrate into cancer sites, recognize cancer cells and elicit cytotoxicity toward cancer cells.
Hence, resistance mechanisms governing the anti-cancer immunity, especially those in the TME, can still dampen the efficiency of cancer vaccines and are being explored to potentiate cancer vaccines. The most critical function of cancer vaccines is to present cancer antigens to prime and activate T cells and induce anti-cancer immunity.
In many cancers, little or no anti-cancer immunity exists in patients that manifests as cold tumors with little immune cell infiltration at the tumor sites.
These cold tumors usually do not respond to ICBs, as there is no ammunition to fire at cancer cells upon removal of the brake by ICBs. To improve their efficacy, cancer vaccines have been extensively studied to be combined with adjuvant agents, such as a TLR-3 agonist poly-ICLC, to stimulate immune response.
Many trials are currently ongoing to determine the efficacy and toxicity of cancer vaccines in combination with cytokines.
For example, IL-2 plays critical roles in key functions of immune response. In addition to IL-2, several other immunostimulatory cytokines are being explored. IL is a multipotent cytokine that stimulates T and NK cells, regulates other cytokines and multiple aspects of immune response.
Several clinical trials are currently ongoing to determine the efficacy and toxicity of IL and cancer vaccine combinations. Extensive preclinical studies as well as many clinical trials are currently ongoing to combine cancer vaccines with ICBs. GXE tirvalimogene teraplasmid is a therapeutic HPV DNA vaccine that encodes HPV and HPV E6 and E7 [ ].
This combination was well tolerated [ ]. Other than concurrent use, ICB has also been shown to have activity as a salvage therapy after cancer vaccine failure. Ott et al. showed that pembrolizumab induced complete responses in melanoma patients after failure of treatment with synthetic long peptide vaccine of tumor neoantigens with poly-ICLC adjuvant [ ].
With a follow-up of almost four years, long-term persistence of neoantigen-specific T cells was still observed with the development of memory T cell phenotype, tumor infiltration and epitope spreading [ ].
One Phase I clinical trial has already been reported with a melanoma-associated antigen recognized by T cells 1 MART-1 peptide vaccine plus IMP, a fusion protein consisting of four LAG-3 extracellular Ig-like domains fused to the Fc fraction of a human IgG1 LAG-3Ig.
A few combination therapies have been approved by the FDA to improve clinical efficacy of ICIs. With increasing research in identifying action-driven reliable biomarkers in guiding clinical immuno-oncology decisions, IO combinations among ACT, novel ICIs, cancer vaccines and small molecule inhibitors are expected.
In this regard, the future of cancer immunotherapy awaits for a truly patient-oriented, individualized approach.
Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. Article CAS PubMed PubMed Central Google Scholar.
Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Article PubMed PubMed Central Google Scholar. Chen DS, Mellman I.
Oncology meets immunology: the cancer-immunity cycle. Article PubMed CAS Google Scholar. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition.
Clin Cancer Res Off J Am Assoc Cancer Res. Article CAS Google Scholar. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al.
Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma.
Cell Rep. Improved survival with ipilimumab in patients with metastatic melanoma. Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Nat Med. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G.
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al.
J Exp Med. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Article CAS PubMed Google Scholar. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL.
J Immunol. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 IP; CXCL10 -deficient mice reveal a role for IP in effector T cell generation and trafficking.
Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochem Biophys Acta. Ungefroren H. Blockade of TGF-beta signaling: a potential target for cancer immunotherapy?
Expert Opin Ther Targets. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al.
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al.
Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death Cell Death Differ. Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al.
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. Gravett AM, Trautwein N, Stevanovic S, Dalgleish AG, Copier J. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.
Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells.
PLoS ONE. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al.
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F. Cancer Res. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting in the antitumor activity of trabectedin.
Dimeloe S, Frick C, Fischer M, Gubser PM, Razik L, Bantug GR, Ravon M, Langenkamp A, Hess C. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur J Immunol.
Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M.
Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M. CAS Google Scholar. Dunn J, Rao S. Epigenetics and immunotherapy: the current state of play.
Mol Immunol. Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, Massengill C, Noyes DR, Martinez GV, Afzal R, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma.
Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Pharm Res. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Oberic L, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers.
Am J Hematol. Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. J Thorac Oncol. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.
Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. Article PubMed PubMed Central CAS Google Scholar. Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH.
Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. Lin L, Hu X, Zhang H, Hu H. Tertiary lymphoid organs in cancer immunology: mechanisms and the new strategy for immunotherapy.
Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, et al.
Germinal Centers Determine The Prognostic Relevance Of Tertiary Lymphoid Structures And Are Impaired By Corticosteroids In Lung Squamous Cell Carcinoma. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al.
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer IMpower : a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, Hermes B, Cay Senler F, Csoszi T, Fulop A, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al.
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, et al.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer CASPIAN : a randomised, controlled, open-label, phase 3 trial. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al.
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer KEYNOTE : a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Article PubMed Google Scholar. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland A, et al.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck KEYNOTE : a randomised, open-label, phase 3 study.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullen A, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, et al.
Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC IMpower : results from a randomized phase III trial. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer.
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
Yoshimoto Y, Oike T, Okonogi N, Suzuki Y, Ando K, Sato H, Noda SE, Isono M, Mimura K, Kono K, et al. Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation.
J Radiat Res. Vermeer DW, Spanos WC, Vermeer PD, Bruns AM, Lee KM, Lee JH. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.
Int J Cancer. Chao MP, Weissman IL, Majeti R. The CDSIRPalpha pathway in cancer immune evasion and potential therapeutic implications.
Curr Opin Immunol. Spitz DR, Azzam EI, Li JJ, Gius D. Cancer Metastasis Rev. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors.
Tigano M, Vargas DC, Tremblay-Belzile S, Fu Y, Sfeir A. Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. Kho VM, Mekers VE, Span PN, Bussink J, Adema GJ. Cell Immunol. Zhang MdJ, Zhang MdL, Yang MdY, Liu MdQ, Ma MdH, Huang MdA, Zhao MdY, Xia MdZ, Liu MdT, Wu MdG.
Int J Radiat Oncol Biol Phys. Article Google Scholar. Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, Zheng W, Mauceri H, Mack M, Xu M, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. De Martino M, Daviaud C, Diamond JM, Kraynak J, Alard A, Formenti SC, Miller LD, Demaria S, Vanpouille-Box C.
Activin A promotes regulatory T-cell-mediated immunosuppression in irradiated breast cancer. Cancer Immunol Res. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.
Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity.
Grabham P, Sharma P. The effects of radiation on angiogenesis. Vasc Cell. Li Y, Patel SP, Roszik J, Qin Y. Hypoxia-driven immunosuppressive metabolites in the tumor microenvironment: new approaches for combinational immunotherapy.
Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, et al. Role of radiation therapy in modulation of the tumor stroma and microenvironment. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
J Clin Invest. Zhang Z, Yang S, Wang Q. Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer.
Biomark Res. Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R. Type I interferon response in radiation-induced anti-tumor immunity.
Semin Radiat Oncol. Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. Mortezaee K, Najafi M. Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives.
Crit Rev Oncol Hematol. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE phase 1 trial.
Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, et al. Cancer Med. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al.
Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al.
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. Jagodinsky JC, Harari PM, Morris ZS. The promise of combining radiation therapy with immunotherapy. Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, et al.
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Vanpouille-Box C, Formenti SC, Demaria S. Toward precision radiotherapy for use with immune checkpoint blockers. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S.
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol. Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, et al.
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM.
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. Radiation abscopal antitumor effect is mediated through p CAS PubMed Google Scholar.
Wang SJ, Jhawar SR, Rivera-Nunez Z, Silk AW, Byun J, Miller E, Blakaj D, Parikh RR, Weiner J, Goyal S. The association of radiation dose-fractionation and immunotherapy use with overall survival in metastatic melanoma patients.
PubMed PubMed Central Google Scholar. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, et al.
Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, et al. The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Eastern cooperative oncology G: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer OPTIMAL, CTONG : a multicentre, open-label, randomised, phase 3 study.
Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.
J Clin Oncol. Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, et al. Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere WR, Guo J, Pan CX. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Cancer Immunol Immunother. Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, Seykora JT, Sapkota B, Gutman DA, Cooper LA, et al. Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression.
Mol Cancer Res. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM. Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja DR, Rosenberg AZ, Jin S, et al. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.
Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2.
Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI.
Clinical significance of defective dendritic cell differentiation in cancer. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al.
Loss of tumor suppressor PTEN function increases B7—H1 expression and immunoresistance in glioma. Han C, Liu T, Yin R. Biomarkers for cancer-associated fibroblasts. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy.
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.
J Exp Clin Cancer Res. Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G, Székvölgyi L. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E, Van den Eynde BJ.
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Huang L, Jiang S, Shi Y.
Tyrosine kinase inhibitors for solid tumors in the past 20 years — Wu K, Yi M, Qin S, Chu Q, Zheng X, Wu K. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp Hematol Oncol. Novel immune checkpoint targets: moving beyond PD-1 and CTLA Mol Cancer. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K.
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, et al.
Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nat Rev Immunol. Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Vignali DA, Collison LW, Workman CJ.
How regulatory T cells work. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP.
Papillary carcinoma of the thyroid: hepatocyte growth factor HGF stimulates tumor cells to release chemokines active in recruiting dendritic cells.
Am J Pathol. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P.
Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL. CCR7 mediates inflammation-associated tumor progression. Immunol Res. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, et al. Cuesta-Mateos C, Fuentes P, Schrader A, Juárez-Sánchez R, Loscertales J, Mateu-Albero T, Vega-Piris L, Espartero-Santos M, Marcos-Jimenez A, Sánchez-López BA, et al.
In response to the targeted therapies, the researchers found, the genomes of some melanoma cells experienced a process known as chromothripsis.
When this happens, bits of DNA can drop out of chromosomes and become restitched into stand-alone circular molecules called ecDNAs. Cancer cells can produce many copies of these ecDNAs—in some cases up to copies.
ecDNAs are an efficient way for cells to increase the number of copies of certain genes and amplify the activity of these genes. As a result, key genes that drive resistance may be present in ecDNAs in large numbers.
After identifying the possible role of the NHEJ pathway and ecDNAs in drug resistance, the researchers tested a strategy for blocking the NHEJ in cells and in animal models. They used a drug that inhibits a protein called DNA-PK, which is essential for the operation of the NHEJ pathway.
In mice implanted with melanoma cells bearing the BRAF V or the NRAS Q61 mutation, the DNA-PK inhibitor delayed or prevented the development of resistance to targeted drugs. Venkatachalam continued. The researchers also found that the NHEJ pathway might play a similar role in some lung and pancreatic cancers.
Venkatachalam said. Lo and his colleagues are developing a clinical trial to test the DNA-PK inhibitor in patients with melanoma. The study will see whether giving the DNA-PK inhibitor with targeted therapies can help delay or prevent tumor resistance.
January 3, , by Elia Ben-Ari. December 15, , by Edward Winstead. November 30, , by Shana Spindler. Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies Subscribe. March 17, , by Edward Winstead Enlarge. Credit: Genes. August CC BY 4. Featured Posts FDA Approves First Immunotherapy Drug for Nasopharyngeal Cancer January 3, , by Elia Ben-Ari.
Virtual Mind—Body Fitness Classes May Offer Benefits during Cancer Treatment December 15, , by Edward Winstead. Combo Treatment Highly Effective for Advanced Bladder Cancer November 30, , by Shana Spindler.
Categories Biology of Cancer. Cancer Risk. Childhood Cancer. Clinical Trial Results. FDA Approvals.
New research Anti-cancer strategies little risk of infection from strategids biopsies. Discrimination at syrategies is linked to high Anti-cancer strategies pressure. Icy fingers and toes: Poor circulation or Raynaud's phenomenon? In fact, there are several approaches that can decrease your cancer risk over the course of your lifetime. Some of them are easy, such as getting recommended health screenings.
0 thoughts on “Anti-cancer strategies”